Beginning at 12:01 a.m. Eastern time on September 29, a zero tariff rate applies to a specific list of specialty drugs, including orphan-designated treatments, plasma-derived therapies, fertility drugs, and cell and gene therapies, imported from 19 named trading partners, under guidance Commerce published September 23. The carve-out sits inside the same Section 232 pharmaceutical program that otherwise imposes a 100% duty on patented drugs, and it applies only when both the product category and the country of origin match what Commerce wrote into the rule. A plasma-derived therapy shipped from one of the 19 listed jurisdictions receives the zero rate; the same product shipped from a country outside that list does not.
What qualifies for the zero rate
Commerce’s Sept. 23 notice lists the categories that qualify: drugs where every approved use carries an orphan designation, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, and certain medical countermeasures and animal-health products. Each category carries its own qualifying test; an orphan designation, for example, only counts if the product has no approved use outside that orphan status.
The cell and gene therapies on the list include the kind of one-time treatments now used against several blood cancers that are more common in older adults, along with therapies for inherited immune disorders. Their price tags are already among the highest in medicine, so a tariff line that runs through this category, rather than around it, carries a different scale of consequence than one running through a widely used generic pill.
Qualifying for zero also depends on where a product comes from. Proclamation 11020 limits the zero rate to products from jurisdictions with trade or security framework agreements with the United States, or to products that meet what the proclamation calls an urgent United States health need. That condition ties eligibility to trade diplomacy as much as to a drug’s medical designation.
The result is narrower than a blanket exemption for specialty drugs. A cell or gene therapy that fits every category on Commerce’s list still faces the standard patented-drug tariff if it is manufactured in a country the proclamation does not cover, because the zero rate requires both the product type and the country of origin to match.
Eligibility that runs through a filing, not a factory: The zero rate depends on where a drug is made; home-cost relief depends on whether a household files for it. Look up the 5 kinds of property-tax relief and the circuit-breaker credit that includes renters in The Senior Property Tax & Home-Cost Relief Kit.
The 19 eligible jurisdictions, and the September 29 start
The 19 jurisdictions named in the Sept. 23 notice are Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam.
That start date, 12:01 a.m. Eastern time on September 29, 2026, is the same one Commerce set for the broader guidance itself, so the specialty-drug carve-out and the general framework around it take effect together rather than on separate timelines.
The list mixes major pharmaceutical-manufacturing economies, including the European Union, Japan, Switzerland and Liechtenstein, and South Korea, with a wider group of developing-economy trading partners such as Bangladesh, Cambodia, El Salvador and Guatemala. All 19 sit on the same zero-rate line regardless of that difference, which is the point of tying eligibility to a country’s trade relationship with the United States rather than to its size as a drugmaker. That is a different sorting principle than the one behind the 100% duty rate Commerce set for patented drugs generally, where the tariff applies once a product is patented, regardless of category.
Whether the zero rate actually lowers a specific patient’s cost still depends on where that patient’s specific product happens to be manufactured today. A plasma-derived clotting-factor concentrate or a fertility hormone made in a country outside the 19-jurisdiction list does not become eligible simply because a chemically similar product made in the European Union does; each import is classified on its own paperwork, not by category alone.
What the zero rate does not fix
A zero import tariff changes what a manufacturer pays to bring a qualifying product into the country. It does not set what an insurer or a Medicare Part D plan charges a patient at the pharmacy or infusion center, where formulary tier and cost-sharing decisions are made separately from any tariff schedule.
Plasma-derived therapies are a category several older patients rely on directly, including treatments drawn from donated plasma for immune deficiencies and clotting disorders. A zero tariff on the imported product removes one cost pressure on the supply chain that produces them, without touching the separate question of what a plan bills a patient once the product reaches a pharmacy or clinic.
The specialty-drug carve-out and the 100% patented-drug rate both trace back to the same directive: Proclamation 11020 told Commerce in April to write detailed tariff schedules for pharmaceutical products, and the Sept. 23 notice is where that work produced both rules at once. That shared origin is why a narrow carve-out for a handful of drug categories and a sweeping tariff on patented drugs generally move on the same regulatory calendar even though they cover different products.
The same Sept. 23 notice that creates this narrow zero-rate lane leaves the broader patented-drug tariff described in a companion guidance the same day fully in place, and it does not extend the zero rate to a qualifying drug category sourced from a jurisdiction outside the 19 named partners. For a plasma-derived therapy or fertility drug manufactured anywhere else, the exemption Commerce built for September 29 simply does not apply.
Relief with narrow edges, too
The Sept. 29 zero rate covers a short list of drug categories from a specific set of countries, and a prescription or its source that falls just outside that list gets no comparable break. Commerce’s notice does not extend the same treatment to every specialty drug or every trading partner.
The Senior Property Tax & Home-Cost Relief Kit is an 11-page kit built around a renewal calendar and filing worksheets, the kind of narrow-eligibility paperwork that also needs checking before assuming a household qualifies.
Compare the eligibility rules in The Senior Property Tax & Home-Cost Relief Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
